Age-related macular degeneration (AMD) is the leading cause of severe, irreversible central vision loss in individuals over 65 years of age throughout much of the developed world. The advent of anti-VEGF therapy has had a great impact in the long-term natural history of this condition, more specifically in patients afflicted with exudative AMD. However, at the end-stages of the disease, therapeutic regimens such as anti-VEGF therapy and/or laser fail to achieve symptom resolution often leading to severe visual impairment and legal blindness. In selected cases, surgery has been advocated as a valid treatment modality in order to preserve vision. This review will evaluate the recent advances in surgical management of AMD, highlighting the different techniques that have been proposed and developed in the last 15 years. In addition, potential therapeutic strategies will be discussed and results obtained in clinical studies will be described. © 2014 Informa UK, Ltd.

Current surgical treatment of age-related macular degeneration

PEIRETTI, ENRICO;
2014

Abstract

Age-related macular degeneration (AMD) is the leading cause of severe, irreversible central vision loss in individuals over 65 years of age throughout much of the developed world. The advent of anti-VEGF therapy has had a great impact in the long-term natural history of this condition, more specifically in patients afflicted with exudative AMD. However, at the end-stages of the disease, therapeutic regimens such as anti-VEGF therapy and/or laser fail to achieve symptom resolution often leading to severe visual impairment and legal blindness. In selected cases, surgery has been advocated as a valid treatment modality in order to preserve vision. This review will evaluate the recent advances in surgical management of AMD, highlighting the different techniques that have been proposed and developed in the last 15 years. In addition, potential therapeutic strategies will be discussed and results obtained in clinical studies will be described. © 2014 Informa UK, Ltd.
Age-related macular degeneration; Choroidal neovascularization; Geographic atrophy; Pars plana vitrectomy; Retinal pigment epithelium cells suspension; Tissue plasminogen activator; Ophthalmology; Biomedical Engineering; Optometry
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11584/104084
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact